Rankings
▼
Calendar
CTNM Q4 2024 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$504M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
$85M
Net Income
-$15M
EPS (Diluted)
$-0.65
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$10M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$213M
Total Liabilities
$15M
Stockholders' Equity
$198M
Cash & Equivalents
$22M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
$85M
-$10M
+975.8%
Net Income
-$15M
-$8M
-87.5%
← FY 2024
All Quarters
Q1 2025 →